Table 3.
RR and 95% CI per cumulative active bone marrow dose category and ERR/100 mGy by type of malignancy—analyses stratified on sex, birth cohort and country
| a. Lymphoid malignancies other than HL | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABM dose range (mGy) | Lymphoid malignanciesa | |||||||||||||||
| NHLb | ||||||||||||||||
| All NHL (n = 387) | Mature B cell (n = 204) | Mature T and NK cell (n = 29) | Precursor cell (n = 140) | |||||||||||||
| # | RR | 95% CI | # | RR | 95% CI | # | RR | 95% CI | # | RR | 95% CI | |||||
| [0,5) | 53 | 1.00 | 32 | 1.00 | 7 | 1.00 | 13 | 1.00 | ||||||||
| [5,10) | 71 | 1.12 | 0.78 | 1.62 | 48 | 1.32 | 0.84 | 2.09 | 6 | 0.86 | 0.28 | 2.67 | 15 | 0.71 | 0.33 | 1.51 |
| [10,15) | 85 | 1.89 | 1.32 | 2.72 | 42 | 1.87 | 1.16 | 3.04 | 3 | 0.67 | 0.17 | 2.74 | 35 | 1.71 | 0.88 | 3.35 |
| [15,25) | 87 | 1.57 | 1.08 | 2.28 | 36 | 1.44 | 0.86 | 2.41 | 7 | 1.58 | 0.50 | 4.95 | 40 | 1.31 | 0.66 | 2.60 |
| [25,50) | 60 | 2.08 | 1.40 | 3.10 | 29 | 2.18 | 1.28 | 3.71 | 4 | 1.66 | 0.45 | 6.06 | 25 | 1.63 | 0.79 | 3.36 |
| [50+] | 31 | 3.00 | 1.87 | 4.81 | 17 | 3.63 | 1.95 | 6.76 | 2 | 2.45 | 0.47 | 12.71 | 12 | 2.10 | 0.91 | 4.85 |
| P for trend | 0.038 | 0.011 | 0.046 | 0.133 | ||||||||||||
| # | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 387 | 2.51 | 1.14 | 4.73 | 204 | 3.15 | 1.17 | 6.88 | 29 | 2.85 | −0.20 | 20.23 | 140 | 1.26 | −0.05 | 4.34 | |
| b. HL and myeloid malignancies | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphoid malignanciesa | Myeloid malignanciesc | |||||||||||
| ABM dose range (mGy) | HL (n = 190) | AML and related precursor neoplasms + ALMP/ALAL (n = 80) | MPN + MDS + MDS/MPN (n = 115) | |||||||||
| # | RR | 95% CI | # | RR | 95% CI | # | RR | 95% CI | ||||
| [0,5) | 38 | 1.00 | 13 | 1 | 20 | 1 | ||||||
| [5,10) | 49 | 1.01 | 0.65 | 1.55 | 15 | 0.81 | 0.38 | 1.74 | 31 | 1.28 | 0.72 | 2.29 |
| [10,15) | 38 | 1.32 | 0.82 | 2.10 | 15 | 1.18 | 0.54 | 2.60 | 17 | 1.19 | 0.61 | 2.33 |
| [15,25) | 34 | 1.21 | 0.74 | 1.98 | 15 | 1.01 | 0.45 | 2.27 | 24 | 1.46 | 0.76 | 2.79 |
| [25,50) | 20 | 1.36 | 0.77 | 2.38 | 15 | 2.01 | 0.90 | 4.47 | 15 | 1.75 | 0.86 | 3.58 |
| [50+] | 11 | 2.15 | 1.08 | 4.30 | 7 | 2.61 | 0.99 | 6.90 | 8 | 2.61 | 1.10 | 6.20 |
| P for trend | 0.004 | 0.04 | 0.01 | |||||||||
| # | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 190 | 1.24 | 0.08 | 3.28 | 80 | 2.39 | 0.11 | 8.17 | 115 | 1.51 | −0.15 | 5.06 | |
Values are shown in RR, ERR/100 mGy and 95% CI. Statistically significant values are shown in bold.
aOne case of lymphoid malignancy could not be classified as HL or NHL—ICD-O-3, 1st revision code 9820.
bFourteen NHL cases could not be classified on the basis of cell type—ICD-O-3, 1st revision code 9590.
cEight cases could not be classified by subgroup: four cases of AL NOS, one acute biphenotypic leukemia and three cases of myeloid leukemia NOS—ICD-O-3, 1st revision codes 9801, 9805 and 9860, respectively.
#, number of hematological malignancy cases.